Sysmex Corporation
6869
Rang in aandelen
#2549
Sysmex Corporation, headquartered in Kobe, Japan, and established in 1968... Sysmex Corporation, headquartered in Kobe, Japan, and established in 1968 (originally known as TOA Medical Electronics Co., Ltd. until its rebranding in October 1998), specializes in the development, manufacturing, and global distribution of advanced diagnostic instrumentation, chemical reagents, and associated software. Its comprehensive product portfolio addresses various diagnostic needs. In hematology, it offers instruments for both three-part and five-part white blood cell differentiation, alongside efficient transport systems designed for high-volume laboratory testing. For urinalysis, the company provides systems capable of analyzing urine formed sediment. Its offerings extend to automated immunochemistry systems, which are adept at performing assays with minute sample quantities, complemented by reagents for detecting infectious diseases and tumor markers. Sysmex also manufactures flow cytometers, crucial for the analysis involved in diagnosing conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Beyond these core areas, the company is deeply involved in oncology diagnostics, developing systems for detecting cancer lymph node metastasis and cancer genome profiling, as well as offering cytogenetic testing and specialized lab assay services. Sysmex also contributes to digital medicine through the development and sale of software for diagnostic information systems, alongside the creation, operation, and maintenance of IT solutions, platforms, and applications in this field. Its activities further encompass the development and sale of nucleic acid analogs, the full lifecycle management (marketing, development, design, manufacture, sale, and after-sales support) of medical robots, and the distribution and post-sales support for medical devices and reagents used in biotechnology, medical technology, and molecular cell analysis. Sysmex serves a diverse client base, including national, public, and private hospitals, universities, research institutes, and other medical facilities. With a robust international presence, the company exports its products to approximately 190 countries worldwide. Demonstrating its commitment to innovation, Sysmex Corporation maintains a strategic alliance with QIAGEN N.V. for the collaborative development and commercialization of cancer companion diagnostics utilizing Plasma-Safe-SeqS technology.
Aandeelprijs
$12.42
Marktkapitalisatie
$7.48B
Verandering (1 dag)
0.10%
Verandering (1 jaar)
2.57%
Land
JP
Handel Sysmex Corporation (6869)
Categorie
Healthcare
Operationele marge voor Sysmex Corporation (6869)
Operationele marge op 2026 TTM: 0.00%
Volgens de meest recente financiële rapporten en aandelenkoers van Sysmex Corporation is de huidige operationele marge (TTM) 0.00%. Eind 2026 had het bedrijf een operationele marge van 0.00%.
Geschiedenis van de operationele marge van Sysmex Corporation van 2026 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| Niet genoeg gegevens voor de verstrekte datums. | ||
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 31.28% | - |
US
|
|
| 12.36% | - |
FR
|
|
| 0.00% | - |
JP
|
|
| 9.83% | - |
US
|
|
| 0.00% | - |
CH
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.